Board of Directors

Michael Wyzga, Chair of Board of Directors
Mr. Wyzga is an accomplished biopharmaceutical industry leader with decades of strategic, management and operational experience at companies at many stages of growth, including companies focused on rare diseases and cancer. From 1998 to 2011, Mr. Wyzga held various senior leadership positions at Genzyme Corporation, a global biotechnology company, including serving as its Executive Vice President, Finance and Chief Financial Officer. Between December 2011 and November 2013, Mr. Wyzga served as President and Chief Executive Officer and a member of the Board of Directors of Radius Health, a biopharmaceutical company focused on developing new therapeutics for the treatment of osteoporosis and women’s health conditions. Currently, Mr. Wyzga is the CEO and President of MSW Consulting Inc. Additionally, Mr. Wyzga serves on the Board of Directors for several biopharmaceutical companies, including Akebia Therapeutics, Inc., Exact Sciences Corporation, and GenSight Biologics. Mr. Wyzga received a BS from Suffolk University and an MBA from Providence College.
Isaac Blech
Mr. Blech is a biotechnology industry entrepreneur and has spent the last 33 years leading pioneering companies in the space including Celgene Corporation, ICOS Corporation, Pathogenesis Corporation, Nova Pharmaceutical Corporation and Genetic Systems Corporation. Currently, Mr. Blech is a Board Member of Edge Therapeutics, Inc., Cerecor, Inc., ContraFect Corporation, Medgenics, Inc., Centrexion Corporation, and RestorGenex Corporation. Mr. Blech holds a BA from Baruch College.
Gary J. Bridger, PhD
Gary J. Bridger, PhD, is a leader who has contributed to the high growth and success of many biotechnology companies with his expertise in financing, corporate planning and R&D strategy. Dr. Bridger was a co-founder and Chief Scientific Officer of AnorMED, Inc., through its acquisition by Genzyme in 2007. Previously, he served as a Board member for Alder Biopharmaceuticals, as Executive Vice President of Research and Development of Xenon Pharmaceuticals, and as Managing Director at Five Corners Capital. Currently, he is a Board member of Aquinox Pharmaceuticals and X4 Pharmaceuticals. Dr. Bridger holds a PhD in Organic Chemistry from the University of Manchester Institute of Science and Technology.
Michael Gilman, PhD
Dr. Gilman is a scientifically trained executive with over 20 years of experience in entrepreneurial biotechnology companies. He is currently CEO and Chair of the Board for Arrakis Therapeutics and CEO and Director for Obsidian Therapeutics, and is a co-Founder of X4. In addition, Dr. Gilman currently serves as an Advisor at Atlas Venture and on the Board of Directors of Scholar Rock. Previously, he was Founder and Chief Executive Officer of Padlock Therapeutics, a venture-funded company focused on autoimmune disease, acquired by Bristol-Myers Squibb in 2016. Prior to Padlock, he founded Stromedix, a company developing novel anti-fibrotic therapies, which was sold to Biogen Idec in 2012. Prior to that, he led all discovery research activities at Biogen Idec. Before that, Dr. Gilman served as chief scientific officer of ARIAD Pharmaceuticals and on the scientific staff at Cold Spring Harbor. Dr. Gilman received his PhD in Biochemistry from the University of California, Berkeley, and was a postdoctoral fellow in the laboratory of Dr. Robert Weinberg at the Whitehead Institute.
Paula Ragan, PhD
Dr. Ragan has more than 15 years of experience building and leading companies in the biotechnology industry. Most recently, Dr. Ragan consulted as Chief Business Officer at Lysosomal Therapeutics Inc. (LTI), an Atlas Venture portfolio company, where she led the company’s business activities. Prior to LTI, Dr. Ragan held leadership roles in corporate development and operations at Genzyme/Sanofi where she led strategic partnering efforts for Genzyme’s Rare Disease business and headed the supply chain planning for Genzyme’s flagship commercial products. Other professional roles include business roles at Hydra Biosciences, Oscient Corporation and Celera Corporation. Dr. Ragan received her PhD from MIT and completed post-doctoral studies at Harvard Medical School.
Alan Walts, PhD
Dr. Walts brings over 25 years of industry experience in corporate venture capital, business development, research and development, and general management and is a co-founder of X4. Currently, Dr. Walts is a Venture Partner at Advent Venture Partners, a business advisor to Henri Termeer and an advisor to various life science companies. He is a member of the Board of Directors and Chief Business Advisor at Aura Biosciences, Founder and Executive Chairman of Artax Biopharma and Founder and board member of Arrakis Therapeutics. Prior to Advent, Dr. Walts held several leadership roles at Genzyme and Sanofi including Senior Advisor & Senior Vice President, Sanofi-Genzyme BioVentures and Senior Vice President, Corporate Development. Alan received a PhD in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh.